7 terminated. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 7 |
| Phase 2 | 3 | Terminated 3 |
Follow Advanced Malignant Solid Neoplasm: new trials by email Literature Review of Advanced Malignant Solid Neoplasm trials Research Report on Advanced Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy - Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 13 | 2021-03-29 | 2026-03-03 |
| SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL Anti-TGF-beta Monoclonal Antibody SAR-439459, Cemiplimab - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Terminated | M.D. Anderson Cancer Center | 3 | 2021-02-09 | 2023-08-14 |
| CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc, Placebo Administration - Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Tianhong Li | 3 | 2020-10-30 | 2026-08-10 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Terminated | M.D. Anderson Cancer Center | 84 | 2017-10-31 | 2026-07-22 |
| Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Advanced Malignant Solid Neoplasm, Anal Carcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 79 | 2015-10-21 | 2026-01-21 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies Capecitabine, Carboplatin, Cyclophosphamide - Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Terminated | M.D. Anderson Cancer Center | 221 | 2015-06-26 | 2025-06-04 |
Neoplasm Metastasis (5) · Lung Neoplasms (4) · Carcinoma, Renal Cell (2) · Adrenal Gland Neoplasms (1) · Anus Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Fallopian Tube Neoplasms (1) · HIV Infections (1) · Liver Neoplasms (1) · Melanoma (1) · Ovarian Neoplasms (1) · Sarcoma, Kaposi (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (6) · Neoplastic Processes (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Lung Diseases (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Adenocarcinoma (3) · Carcinoma (3) · Neoplasms, Glandular and Epithelial (3) · Urogenital Diseases (3) · Digestive System Diseases (2)
Nivolumab (4) · CTLA-4 Antigen (2) · Ipilimumab (2) · pembrolizumab (2) · Biopsy (1) · Capecitabine (1) · Carboplatin (1) · Cyclophosphamide (1) · Disulfides (1) · Doxorubicin (1) · Everolimus (1) · Fluorouracil (1) · Immunoglobulin G (1) · Irinotecan (1) · Leucovorin (1)
M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (1) · Tianhong Li (1)
United States (7) · Australia (1)
Aung Naing, MD (1) · James Welsh (1) · Lakshmi Rajdev (1) · Sarina A Piha-Paul (1) · Siqing Fu, MD, PHD (1) · Tianhong Li, MD, PhD (1) · Timothy A Yap (1)
PMID 33677480, PMID 33909232, PMID 34562230, PMID 34965890, PMID 37129197, PMID 37314501, PMID 37962072, PMID 39816915, PMID 39945382, PMID 40580957
P30CA093373 (1), U01CA121947 (1), UM1CA121947 (1)